Landscape of Gout in French Polynesia.

NCT07343336 | Recruiting

• 1 other identifier: RC-P00126
• Study Type: observational
• Target: 2,750
• Locations: 1 country
• Sites: 6

Brief Summary

The aim of this research is to characterise the genetic and molecular landscape of gout, inflammation and metabolic diseases, as well as the associated molecular, anthropomorphic and pathological characteristics.

Conditions

Gout Disease; Metabolic Diseases; Inflammation

Keywords

Gout disease; metabolic disease; inflammation

Outcome Measures

Primary Outcomes (1)

• GWAS-identified associations between population-enriched genetic variants and health-related traits

  Effect estimates (odds ratios or beta coefficients) for statistically significant associations between population-enriched genetic variants and predefined health-related traits identified through GWAS.

  12 month

Secondary Outcomes (9)

• Multiple correlation between gout, hyperuricemia, type 2 diabetes and obesity

  12 month

• Incidence rate of gout or HU in French Polynesia between 2021 and 2025

  4 years

• Proportion of each type of urate-lowering therapy prescribed annually between 2019 and 2025

  4 years

• Incidence of major adverse cardiovascular events (MACE) in patients with gout, diabetes, or obesity

  12 month

• Determinants of progression from asymptomatic hyperuricemia (in 2021) to gout (in 2025)

  4 years

Study Arms (3)

General Population Group

Patients aged between 18 and 75 years old who did not take part in the TOPATA study in 2021 and who visit their general practitioner for a consultation (for whatever reason)

Other: Epidemiological study; Diagnostic Test: Blood and urine tests

Gout Group

Patients aged between 18 and 75 years old who are treated at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard. * There is a tophaceous gout subgroup: patients with tophaceous gout. * And a gout attack subgroup: patients presenting with a gout crisis.

Other: Epidemiological study; Diagnostic Test: Blood and urine tests

Follow-up group 2021

Patients aged between 18 and 75 years old who were included in the TOPATA study in 2021 and for whom genetic and biological samples during the 2021 study were taken. Patients must have had hyperuricaemia without signs of gout OR without hyperuricaemia or gout at the time of inclusion in the 2021 TOPATA study.

Other: Epidemiological study; Diagnostic Test: Blood and urine tests

Interventions

Epidemiological study OTHER

Collection of sociodemographic data, collection of treatment data, standard and clinical ophthalmological examination, physical and biological measurements, clinical characteristics specific to chronic and metabolic diseases, questionnaires (gout questionnaire, health assessment questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, sleep quality, pain scale (EVA), personal and family history) will be performed.

Follow-up group 2021; General Population Group; Gout Group

Blood and urine tests DIAGNOSTIC_TEST

Collection of blood and urine samples for genetic, biochemical, omics, and biobank analyses, in order to characterize cardiometabolic health markers will be performed.

Follow-up group 2021; General Population Group; Gout Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

General population group: Participants will be recruited by general practitioners or study nurses during consultations in community-based practices. The objective is to include a representative general population sample, with no specific reason for consultation required or excluded. Gout group: Patients will be recruited at the Rheumatology Clinic of the Taaone Hospital Center (CHT) in Papeete when presenting with gout symptoms, either tophaceous gout or an acute flare within the previous 48 hours. 2021 follow-up group: Participants from the TOPATA study conducted in 2021 will be recontacted by telephone to assess willingness to participate, followed by an in-person inclusion visit. Only individuals currently living in Tahiti will be contacted. Nurses will be responsible for recruitment, biological sample collection, physical measurements, and questionnaire administration.

You may qualify if:

• All participants:
• Age between 18 and 75 years old inclusive
• Signature of informed consent
• Fasting for the collection of biological samples
• Declared Polynesian ancestry
• Affiliated to a social security scheme
• General population group :
• Not having participated to the 2021 TOPATA study
• Visiting a general practitioner (for whatever reason)
• Gout Group :
• Managed at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard.
• Tophaceous gout sub-group:
• Present with tophaceous gout.
• Gout crisis subgroup:
• Be within 48 hours of the onset of a gout attack

You may not qualify if:

• All participants :
• Refusal or inability to understand or give consent
• Physical inability to follow and respect the protocol
• st degree relative\*,
• Person under guardianship or trusteeship
• Pregnant or breast-feeding woman
• \* If several relatives from the same household are eligible to participate, only one person may be included in the study. The choice is left to the discretion of the investigator or the first person met. However, both members of a couple (e.g. husband and wife) may participate.
• General population group :
• Unable to return for sampling if required.
• Gout group :
• Person wearing a knee prosthesis
• People suffering from other inflammatory rheumatic diseases

Sponsors & Collaborators

• Lille Catholic University: lead
• Variant Bio, Inc.: collaborator

Study Sites (6)

Medical Office Dr Antoine Scuiller

Faa'a, 98702, French Polynesia

RECRUITING

Medical Office Dr Cedric Gueguen

Papeete, 98713, French Polynesia

RECRUITING

Medical Office Dr Voradeth Nouanesengsy

Papeete, 98714, French Polynesia

RECRUITING

CH de Polynesie Française Papeete

Pirae, 98716, French Polynesia

NOT YET RECRUITING

Medical Office Dr Nanethida Nouanesengsy

Pirae, 98716, French Polynesia

RECRUITING

Medical Office Dr Raphael Habib

Pirae, 98716, French Polynesia

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample, urine sample, synovial fluid

MeSH Terms

Conditions

Metabolic Diseases; Inflammation

Interventions

Epidemiologic Studies; Blood Specimen Collection; Urinalysis

Condition Hierarchy (Ancestors)

Nutritional and Metabolic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Epidemiologic Study Characteristics; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Clinical Chemistry Tests; Diagnostic Techniques, Urological

Study Officials

• Tristan Pascart, Professor

  GHICL

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marie De Solere

CONTACT

+33 3 20 22 59 31; desolere.marie@ghicl.net

Berenice Marchant

CONTACT

+33 3 20 22 57 51; marchant.berenice@ghicl.net

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2025
• First Posted: January 15, 2026
• Study Start: September 2, 2025
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: January 15, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

FR (6)